15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering Corvus Pharmaceuticals Inc, 5 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $27.00 to $42.00, a moderate spread. The average target of $34.00 sits 163% above the current $12.93. The rating mix has stayed broadly stable, with Buy-side ratings easing from 6 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.19 next quarter toward $-0.95 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Moderate Buy
Strong Buy00%
Buy5100%
Hold00%
Sell00%
Strong Sell00%
Based on 5 analysts giving stock ratings to Corvus Pharmaceuticals Inc.
As of Jul, 5 of 5 firms rate CRVS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CRVS EPS & revenue forecast
EPS · NEXT QUARTER
$-0.19
Range $-0.22 – $-0.17 · 3 analysts · +58% YoY
Next period, 3 analysts expect Corvus Pharmaceuticals Inc to earn $-0.19 a share (range $-0.22 – $-0.17), versus $-0.12 a year earlier. Full-year consensus is $-0.72, growing to $-0.95 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 3 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $5.7M next year.
Top analysts covering Corvus Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CRVS.
#1
Sean Lee
HC Wainwright & Co. · Rank #191
Buy
$27.00+108.9% to target
Overall win rate
43%
+ Follow
#2
Jeff Jones
Oppenheimer · Rank #197
Buy
$33.00+155.3% to target
Overall win rate
34%
+ Follow
#3
Li Watsek
Cantor Fitzgerald · Rank #218
Buy
No targeton CRVS
Overall win rate
38%
+ Follow
#4
Aydin Huseynov
Ladenburg Thalmann · Rank #361
Buy
$21.00+62.5% to target
Overall win rate
34%
+ Follow
#5
Paul Choi
Goldman Sachs
Buy
$40.00+209.5% to target
Coverage
—
+ Follow
CRVS stock forecast FAQ
What is CRVS's average 12-month price target?+
The 5 analysts with a live target average $34.00 for Corvus Pharmaceuticals Inc over the next 12 months, ranging from a $42.00 high to a $27.00 low.
Is CRVS stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 5 analyst ratings, 5 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for CRVS?+
The Street-high target is $42.00 (Jefferies), and the Street-low is $27.00 (HC Wainwright & Co.). The average of all 5 active targets is $34.00.
How many Wall Street analysts cover CRVS?+
5 analysts have an active rating on Corvus Pharmaceuticals Inc, and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering CRVS?+
Among analysts who currently cover CRVS, Sean Lee of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #191). Their current call is Buy with a $27.00 target.
What is Corvus Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.19 per share (range $-0.22 – $-0.17) across 3 analysts. Full-year EPS is projected at $-0.72, rising to $-0.95 the following year.
How much revenue is Corvus Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $5.7M next year.
Have analysts been upgrading or downgrading CRVS lately?+
As of Jul, 5 of 5 firms rate CRVS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CRVS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
